Beta Bionics Prices $150 Million Stock Offering

Beta Bionics priced an underwritten offering of 7,652,175 common shares at $17.25 each and pre-funded warrants for 1,043,484 shares at $17.2499 each, generating expected gross proceeds of $150 million before expenses. The warrants have a nominal $0.0001 exercise price and were offered in lieu of shares to certain investors, allowing them to obtain similar economic exposure without immediately exceeding beneficial-ownership limits. The company may use the proceeds to commercialize its Mint patch pump, expand manufacturing, fund research and development, pursue strategic opportunities, and support working capital. Beta Bionics also granted underwriters a 30-day option to purchase up to 1,304,348 additional shares. The financing follows FDA clearance of Mint and its 3D Intelligence dosing algorithm, with commercialization expected to begin in the first quarter of 2027.